Monitoring Your Goiter Over Time
At a Glance
For a benign, nontoxic goiter, follow-up is tailored to the ultrasound risk pattern and may include neck exams, TSH blood tests, and repeat ultrasound. Small measurement changes are common; significant growth or new symptoms may lead to further evaluation.
When you are diagnosed with a benign, nontoxic goiter that isn’t causing symptoms, your doctor will likely recommend active surveillance (often called “watch and wait”). This is not “doing nothing.” Instead, it is a proactive, risk-stratified plan to ensure that your thyroid remains stable and that no new concerns develop over time [1][2].
The Surveillance Schedule
There is no single “one-size-fits-all” schedule for thyroid monitoring. Follow-up depends on whether you have a diffuse goiter or distinct nodules, your ultrasound risk pattern, whether a biopsy was performed, and the specific clinical guidelines your doctor follows (such as ATA or ACR guidelines) [3][4].
- Individualized Timing: Some very low-risk nodules require no routine repeat imaging at all. Higher-risk nodules may be checked 6 to 12 months after the initial diagnosis to establish stability [5].
- Long-term Monitoring: If imaging shows no change, intervals between scans often stretch out over several years [5][6].
- Comprehensive Review: Surveillance is not just about ultrasounds. Your follow-up visits should also include a clinical neck exam to check for physical changes and blood tests (like TSH) to ensure your thyroid continues to function normally [1].
Defining “Significant Growth”
One of the main reasons for follow-up scans is to check for nodule growth. However, small variations in measurements are normal and often due to slight differences in how the ultrasound probe was held [7][8]. To account for this, doctors use specific thresholds to define significant growth [9]:
- The 20/2 Rule: An increase of at least 20% in at least two different dimensions (length, width, or depth), with a minimum absolute increase of at least 2 mm [9][10].
- The 50% Rule: An increase in the total calculated volume of the nodule by 50% or more [10][9].
It is important to remember that growth alone is usually not a sign of cancer [9]. Most benign nodules grow slowly over many years. If your nodule reaches these thresholds, your doctor will look for new “suspicious” features on the ultrasound before deciding if a repeat FNA biopsy is necessary [11][12].
Managing “Scanxiety” and the Emotional Burden
Living with a goiter that requires long-term monitoring can cause a specific type of stress often called scanxiety [13].
To help manage the emotional impact of surveillance:
- Request a Written Plan: Ask your doctor for a clear, written surveillance plan. It should include the date for your next review, your current TSH result, your nodule measurements, and what specific symptoms should prompt an earlier call [14].
- Understand the Risks: Remind yourself that benign nodules rarely transform into cancer. When a malignancy is found later in surveillance, it is usually because it was a new lesion that developed or an area that was missed during initial sampling, not because a truly benign nodule spontaneously turned malignant [6].
- Focus on Symptoms: Day-to-day, you don’t need to check your neck in the mirror. Instead, stay aware of your physical comfort. If you notice new, persistent trouble swallowing, a change in your voice, or breathlessness, contact your specialist for a review regardless of when your next scan is scheduled [1].
Common questions in this guide
How often will I need an ultrasound for a benign nontoxic goiter?
How do doctors decide whether a thyroid nodule has grown significantly?
Does a growing thyroid nodule automatically mean cancer or another biopsy?
What happens at a routine follow-up visit for a nontoxic goiter?
Which new goiter symptoms mean I should call before my next scan?
How can I cope with anxiety while my goiter is being monitored?
Get notified when new evidence is published on nontoxic goiter.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Long-Term Surveillance for Benign Thyroid Nodules.
Macera M, Melcarne R, Grani G
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(1)):77-86 doi:10.1016/j.eprac.2025.07.021.
PMID: 40769308 - 2
Contemporary Thyroid Nodule Evaluation and Management.
Grani G, Sponziello M, Pecce V, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(9)) doi:10.1210/clinem/dgaa322.
PMID: 32491169 - 3
Implementing Key Changes in the American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types.
Twining CL, Lupo MA, Tuttle RM
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; (24(9)):833-840 doi:10.4158/EP-2018-0130.
PMID: 30308136 - 4
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE.
Gharib H, Papini E, Garber JR, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2016; (22(5)):622-39 doi:10.4158/EP161208.GL.
PMID: 27167915 - 5
Ultrasound Follow-Up of Benign Thyroid Nodules: A Scoping Review.
Chou R, Dana T, Mayson SE, et al.
Thyroid : official journal of the American Thyroid Association 2023; (33(4)):420-427 doi:10.1089/thy.2022.0692.
PMID: 36800900 - 6
Malignancy rates in thyroid nodules: a long-term cohort study of 17,592 patients.
Grussendorf M, Ruschenburg I, Brabant G
European thyroid journal 2022; (11(4)).
PMID: 35635802 - 7
Inter-observer variation in ultrasound measurement of the volume and diameter of thyroid nodules.
Choi YJ, Baek JH, Hong MJ, Lee JH
Korean journal of radiology 2015; (16(3)):560-5 doi:10.3348/kjr.2015.16.3.560.
PMID: 25995685 - 8
Interobserver Reproducibility in Sonographic Measurement of Diameter and Volume of Papillary Thyroid Microcarcinoma.
Chung SR, Choi YJ, Lee SS, et al.
Thyroid : official journal of the American Thyroid Association 2021; (31(3)):452-458 doi:10.1089/thy.2020.0317.
PMID: 33287640 - 9
The natural history of benign thyroid nodules.
Durante C, Costante G, Lucisano G, et al.
JAMA 2015; (313(9)):926-35 doi:10.1001/jama.2015.0956.
PMID: 25734734 - 10
Changes in the Volume and Diameter of Benign Thyroid Nodules: A 10-Year Follow-Up Study.
Erdoğan MF, Bahçecioğlu AB, Avcı Merdin F, et al.
Thyroid : official journal of the American Thyroid Association 2025; (35(1)):31-40 doi:10.1089/thy.2024.0405.
PMID: 39692610 - 11
Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules.
Maino F, Bufano A, Dalmazio G, et al.
Thyroid : official journal of the American Thyroid Association 2021; (31(3)):446-451 doi:10.1089/thy.2020.0351.
PMID: 32718278 - 12
Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer.
Falch C, Axt S, Scuffi B, et al.
World journal of surgical oncology 2015; (13()):338 doi:10.1186/s12957-015-0752-x.
PMID: 26684213 - 13
Anxiety disorders in patients with thyroid nodules vs. thyroid cancer: a retrospective cohort study.
Kornelius E, Lo SC, Huang CN, et al.
Frontiers in endocrinology 2025; (16()):1539442 doi:10.3389/fendo.2025.1539442.
PMID: 40235655 - 14
Thyroid nodules: diagnosis and management.
Grani G, Sponziello M, Filetti S, Durante C
Nature reviews. Endocrinology 2024; (20(12)):715-728 doi:10.1038/s41574-024-01025-4.
PMID: 39152228
This page explains follow-up for a benign, nontoxic goiter for informational purposes only and does not constitute medical advice. Your clinician should set your ultrasound schedule and interpret changes in your symptoms, TSH results, and nodule measurements.